Harrow Health Q3 Adj EPS $(0.09) Misses $0.04 Estimate, Sales $34.27M Miss $37.58M Estimate
Portfolio Pulse from Benzinga Newsdesk
Harrow Health (NASDAQ:HROW) reported a Q3 adjusted EPS of $(0.09), missing the $0.04 estimate, and sales of $34.27M, missing the $37.58M estimate. This represents a 50% decrease in EPS and a 50.13% increase in sales from the same period last year.
November 13, 2023 | 9:04 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Harrow Health reported a significant miss in Q3 adjusted EPS and sales, with a 325% miss on EPS estimates and an 8.82% miss on sales estimates compared to analyst expectations.
The substantial miss in both EPS and sales compared to analyst estimates is likely to negatively impact investor sentiment and the stock price of Harrow Health in the short term. The magnitude of the miss, especially in EPS, suggests that the company's financial performance is significantly below market expectations, which can lead to a decrease in stock price as investors adjust their valuation of the company.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100